Clinton E. Leysath
National Institutes of Health
15 Papers
150 Citations
Clinton E. Leysath is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Anthrax toxin & Bacillus anthracis. The author has an hindex of 12, co-authored 15 publications. Previous affiliations of Clinton E. Leysath include Tufts University.
Chat about Author
Papers
The sub-nanomolar binding of DNA-RNA hybrids by the single-chain Fv fragment of antibody S9.6
Damilola D. Phillips,David N. Garboczi,Kavita Singh,Zonglin Hu,Stephen H. Leppla,Clinton E. Leysath +5 more
TL;DR: The monoclonal antibody S9.6 binds DNA–RNA hybrids with high affinity, making it useful in research and diagnostic applications, such as in microarrays and in the detection of R‐loops.
A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.
Jacqueline M. Tremblay,Jean Mukherjee,Clinton E. Leysath,Michelle Debatis,Kwasi Ofori,Karen Baldwin,Courtney Boucher,Rachel Peters,Gillian Beamer,Abhineet S. Sheoran,Daniela Bedenice,Saul Tzipori,Charles B. Shoemaker +12 more
TL;DR: In this article, a panel of heavy-chain-only antibody (Ab) V(H) (VHH) domains were identified that neutralized Stx1 and/or Stx2 in cell-based assays.
97
A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model.
Jean Mukherjee,Jacqueline M. Tremblay,Clinton E. Leysath,Kwasi Ofori,Karen Baldwin,Xiaochuan Feng,Daniela Bedenice,Robert P. Webb,Patrick M. Wright,Leonard A. Smith,Saul Tzipori,Charles B. Shoemaker +11 more
TL;DR: A single, easy-to-produce recombinant protein was as efficacious as polyclonal antiserum in a clinically-relevant mouse model of botulism and should have widespread application in antitoxin development and other therapies in which neutralization and/or accelerated clearance of a serum biomolecule can offer therapeutic benefit.
A single VHH-based toxin neutralizing agent and an effector
Jacqueline M. Tremblay,Jean Mukherjee,Clinton E. Leysath,Michelle Debatis,Kwasi Ofori,Karen Baldwin,Courtney Boucher,Rachel Peters,Gillian Beamer,Abhineet S. Sheoran,Daniela Bedenice,Saul Tzipori,Charles B. Shoemaker,Rockville Pike +13 more
- 01 Jan 2013
TL;DR: It is shown that coadministration of effector Ab substantially improved the efficacy of Stx toxin-neutralizing agents to prevent death or kidney damage in mice following challenge with Stx1 or Stx2.
57
A Heterodimer of a VHH (Variable Domains of Camelid Heavy Chain-only) Antibody That Inhibits Anthrax Toxin Cell Binding Linked to a VHH Antibody That Blocks Oligomer Formation Is Highly Protective in an Anthrax Spore Challenge Model
Mahtab Moayeri,Clinton E. Leysath,Jacqueline M. Tremblay,Catherine Vrentas,Devorah Crown,Stephen H. Leppla,Charles B. Shoemaker +6 more
TL;DR: The studies show the potential of VNAs as anthrax therapeutics due to their simple and stable nature, and should be amenable to genetic delivery or administration via respiratory routes.
38